[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599955":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":21,"centralContacts":31,"locations":36,"responsibleParty":49,"collaborators":51,"id":55,"slug":10,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":10,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":78,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Paris Translational Research Center for Organ Transplantation","OTHER",[8,12,15,18],{"label":9,"type":10,"description":11,"interventionNames":10},"Group 1: Classic rejection profile",null,"Active\u002Fchronic AMR or TCMR",{"label":13,"type":10,"description":14,"interventionNames":10},"Group 2: Other rejection profiles","Probable AMR, MVI+DSA- C4d-, borderline or mixed rejection",{"label":16,"type":10,"description":17,"interventionNames":10},"Group 3: Other diagnoses","CMV, CNI toxicity, recurrence, BK nephropathy",{"label":19,"type":10,"description":20,"interventionNames":10},"Group 4: Normal biopsies","No lesions (normal biopsy results)",[22,26,29],{"name":23,"affiliation":24,"role":25},"Evgenia Preka, MD, PhDc","INSERM U970","PRINCIPAL_INVESTIGATOR",{"name":27,"affiliation":24,"role":28},"Alexandre Loupy, MD, PhD","STUDY_CHAIR",{"name":30,"affiliation":24,"role":28},"Valentin Goutaudier, MD, PhD",[32],{"name":23,"role":33,"phone":34,"phoneExt":10,"email":35},"CONTACT","+33 1 44 23 60 00","evgenia.preka@gmail.com",[37],{"facility":38,"status":10,"city":39,"state":10,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":10},"Paris Institute for Transplantation and Organ Regeneration (PITOR)","Paris","75015","France","FR",{"type":44,"coordinates":45},"Point",[46,47],2.3488,48.85341,{"lat":47,"lon":46},{"type":50,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[52],{"name":53,"class":54},"Paris Cardiovascular Research Center (Inserm U970)","OTHER_GOV","100599955",false,"NCT07091214","Molecular Transcriptomics in Diagnosing Pediatric Kidney Transplant Rejection: the PANDA-Kids-ATLAS Study","Precision Allograft Rejection Using Novel Diagnostic Approaches in Kidney Transplantation - Allograft Transcriptomics Landscape Analysis Using Sequencing (the PANDA-Kids-ATLAS Study)","Inclusion Criteria:\n\n* Age ≤ 21 years\n* Single kidney transplant recipients (deceased or living donor)\n* Written informed consent from patients\u002Fguardians\n\nExclusion Criteria:\n\n* Multi-organ transplantation history\n* Biopsies with insufficient tissue",true,"ALL","0 Years","21 Years",{"count":66,"type":67},600,"ESTIMATED","OBSERVATIONAL","Children with kidney failure have markedly increased mortality and face repeated transplantation over their lifetime due to limited allograft half-life (12-15 years). Current biopsy-based diagnoses of rejection (using Banff 2022 criteria) suffer from variability and limited sensitivity. PANDA-Kids-ATLAS will analyze up to 600 pediatric FFPE kidney biopsies across multiple centres using the Banff Human Organ Transplant (B-HOT) NanoString panel to develop and validate molecular classifiers of AMR, TCMR and related phenotypes. A secure REDCap database will integrate molecular, pathological and clinical data, aiming to improve early detection, personalize therapy, and enhance long-term graft survival and patient quality of life.",[71],"Kidney Rejection Transplant",[73,74,75,76,77],"transcriptomics","pediatric kidney transplantation","allograft rejection","precision diagnosis","molecular classifiers","NOT_YET_RECRUITING","2025-07-28",{"date":81,"type":82},"2025-07-29","ACTUAL",{"date":84,"type":67},"2025-09-01",{"date":86,"type":67},"2028-12-31",{"name":5,"class":6},1]